Floatz logo

Rifaximin

Portal Hypertension

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)Small moleculePhase 4 / ApprovedActive
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
55/ 100
Competitive Position
81/ 100

Competitive context

20 Active assets in the Portal Hypertension cohort.

Asset / SponsorPhaseRating
CARVEDILOL
West China Hospital
Phase 4BBB
SIMVASTATIN
Kafrelsheikh University
Phase 4BBB
PROPRANOLOL
West China Hospital
Phase 4BBB
Apixaban
Asian Institute Of Medical Sciences
Phase 4BB
LACTULOSE
University of Michigan
Phase 4BB

View all 50 →

Same molecule, other indications

Rifaximin is also rated in:

hepatic encephalopathyDormant
BBB
Indicative ·
75 / 100
View asset →
cirrhosis of liverDormant
BBB
Indicative ·
72 / 100
View asset →
AscitesDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →